Multicenter prospective study on multivariant diagnostics of autoimmune bullous dermatoses using the BIOCHIP technology
Jazyk angličtina Země Spojené státy americké Médium print-electronic
Typ dokumentu časopisecké články, multicentrická studie
PubMed
32004645
DOI
10.1016/j.jaad.2020.01.049
PII: S0190-9622(20)30133-X
Knihovny.cz E-zdroje
- Klíčová slova
- autoimmune bullous diseases, biochip, immunofluorescence, pemphigoid, pemphigus,
- MeSH
- autoimunitní nemoci krev diagnóza MeSH
- bulózní pemfigoid krev diagnóza imunologie MeSH
- dítě MeSH
- dospělí MeSH
- fluorescenční protilátková technika nepřímá metody MeSH
- lidé středního věku MeSH
- lidé MeSH
- mladiství MeSH
- mladý dospělý MeSH
- pemfigus krev diagnóza imunologie MeSH
- prospektivní studie MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- Check Tag
- dítě MeSH
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- mladiství MeSH
- mladý dospělý MeSH
- mužské pohlaví MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- multicentrická studie MeSH
BACKGROUND: The current standard in the serologic diagnosis of autoimmune bullous diseases (AIBD) is a multistep procedure sequentially applying different assays. In contrast, the BIOCHIP Mosaic technology combines multiple substrates for parallel analysis by indirect immunofluorescence. METHODS: Sera from 749 consecutive, prospectively recruited patients with direct immunofluorescence-positive AIBD from 13 international study centers were analyzed independently and blinded by using (1) a BIOCHIP Mosaic including primate esophagus, salt-split skin, rat bladder, monkey liver, monkey liver with serosa, recombinant BP180 NC16A, and gliadin GAF3X, as well as HEK293 cells expressing recombinant desmoglein 1, desmoglein 3, type VII collagen, and BP230 C-terminus and (2) the conventional multistep approach of the Department of Dermatology, University of Lübeck. RESULTS: In 731 of 749 sera (97.6%), specific autoantibodies could be detected with the BIOCHIP Mosaic, similar to the conventional procedure (725 cases, 96.8%). The Cohen κ for both serologic approaches ranged from 0.84 to 1.00. In 6.5% of sera, differences between the 2 approaches occurred and were mainly attributed to autoantigen fragments not present on the BIOCHIP Mosaic. LIMITATIONS: Laminin 332 and laminin γ1 are not represented on the BIOCHIP Mosaic. CONCLUSIONS: The BIOCHIP Mosaic is a standardized time- and serum-saving approach that further facilitates the serologic diagnosis of AIBD.
Department of Dermatology and Immunodermatology Medical University of Warsaw Warsaw Poland
Department of Dermatology and Venereology Sofia University of Medicine Sofia Bulgaria
Department of Dermatology Beijing University 1st Hospital Beijing China
Department of Dermatology Faculty of Medicine Akdeniz University Antalya Turkey
Department of Dermatology Poznan University of Medical Sciences Poznan Poland
Department of Dermatology School of Medicine University of Belgrade Belgrade Serbia
Department of Dermatology St Anna University Hospital Brno Czech Republic
Department of Dermatology Tel Aviv Sourasky Medical Center Tel Aviv Israel
Department of Dermatology University of Lübeck Lübeck Germany
Institute of Experimental Immunology EUROIMMUN AG Lübeck Germany
Lübeck Institute of Experimental Dermatology Lübeck Germany
Molecular and Cell Biology Laboratory IDI IRCCS Rome Italy
St George Hospital University of New South Wales School of Medicine Sydney Australia
University Institute of Clinical Chemistry and Center of Laboratory Medicine Bern Switzerland
Citace poskytuje Crossref.org
